MTNB - Matinas BioPharma Holdings, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
1.4900
+0.0200 (+1.36%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.4700
Open1.4600
Bid1.5200 x 3000
Ask1.5300 x 900
Day's Range1.4500 - 1.5800
52 Week Range0.5820 - 2.4900
Volume5,808,690
Avg. Volume3,038,954
Market Cap242.483M
Beta (5Y Monthly)2.44
PE Ratio (TTM)N/A
EPS (TTM)-0.1240
Earnings DateNov 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.90
  • GlobeNewswire

    Matinas BioPharma Announces Closing of Public Offering of Common Stock

    Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced the closing  of its underwritten registered public offering of 32,260,000 shares of its common stock, offered at a price to the public of $1.55 per share for gross proceeds of approximately $50.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, Matinas BioPharma has granted the underwriters a 30-day option to purchase up to an additional 4,839,000 shares of its common stock on the same terms and conditions. All of the shares in the offering are being sold by Matinas BioPharma.

  • GlobeNewswire

    Matinas BioPharma Announces Pricing of Public Offering of Common Stock

    Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced the pricing of its underwritten registered public offering of 32,260,000 shares of its common stock, offered at a price to the public of $1.55 per share for expected gross proceeds of approximately $50.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, Matinas BioPharma has granted the underwriters a 30-day option to purchase up to an additional 4,839,000 shares of its common stock on the same terms and conditions. All of the shares in the offering are being sold by Matinas BioPharma.

  • Benzinga

    The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 9) Acceleron Pharma Inc (NASDAQ: XLRN ) Allergan plc (NYSE: ...

  • GlobeNewswire

    Matinas BioPharma Announces Proposed Public Offering of Common Stock

    Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of its common stock. In connection with the offering, Matinas BioPharma intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering.

  • Thomson Reuters StreetEvents

    Edited Transcript of MTNB earnings conference call or presentation 13-Nov-19 1:00pm GMT

    Q3 2019 Matinas BioPharma Holdings Inc Earnings Call

  • Read This Before Selling Matinas BioPharma Holdings, Inc. (NYSEMKT:MTNB) Shares
    Simply Wall St.

    Read This Before Selling Matinas BioPharma Holdings, Inc. (NYSEMKT:MTNB) Shares

    We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...

  • Did Hedge Funds Drop The Ball On Matinas Biopharma Holdings, Inc. (MTNB) ?
    Insider Monkey

    Did Hedge Funds Drop The Ball On Matinas Biopharma Holdings, Inc. (MTNB) ?

    It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]

  • Amarin Stock is at Sky-High Levels Already Assumes All the Good News
    InvestorPlace

    Amarin Stock is at Sky-High Levels Already Assumes All the Good News

    On Friday, Dec. 13, 2019, the FDA approved an expanded cardiovascular claim for Vascepa, a drug produced by Amarin (NASDAQ:AMRN). Prior to this patients with very high triglyceride levels were only ones approved to use Vascepa.Source: Pavel Kapysh / Shutterstock.com Now those with lower levels and other signs of heart or diabetes issues can use it. This vastly expands the population to whom Amarin can sell Vascepa. Those with greater than 150 milligrams per deciliter can now use the drug. Amarin estimates that "millions" (with no specific number associated with that noun) can benefit from its drug.A previous advisory committee had unanimously recommended that the drug be approved. There was a high likelihood that the FDA would approve Vascepa for expanded cardiovascular treatment.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Amarin Stock Includes a Lot of Good NewsAnalysts have already argued that Amarin's Vascepa, its only drug, will bring in greater than $1 billion annually in sales, with peak sales above that. One analyst, Nathan Weinstein, at Aegis believes the drug could hit $2 billion in sales by 2025. His peak price target was $23 per share.The problem is Amarin stock is already very close to that target price, at $21.36 per share. In other words, a lot of the good news is already implied in the valuation of AMRN stock. Another analyst, at Stifel, has put a hold recommendation on Amarin stock. His price target is $28 per share. * 7 'Strong Buy' Stocks to Put on Your Wish List Amarin announced that it expects its 2020 U.S. sales to be between $650 million to $700 million from sales of Vascepa. Seeking Alpha's database of eight analysts have an average estimate of $692 million in revenue for 2020.That puts Amarin stock on a forward price-to-sales ratio of 11.9 times. That is an extremely high valuation metric. It would normally be the number for a conservative stock's price-to-earnings ratio.It implies that a bidder for all of AMRN stock would have to wait almost 12 years before their investment would equal the sales achieved, not earnings. Not too many companies would be willing to do that.Clearly the market expects that sales will climb significantly over the next 12 years. There are tw0 problems with that theory: competition and patent issues. Problems With the ValuationThe FDA is also looking at similar drug studies from: AstraZeneca (NYSE:AZN), whose drug is called Epanova; Acasti Pharma (NASDAQ:ACST), with CaPre; and, Matinas BioPharma (NYSEAMERICAN:MTNB), with its MAT900i drug.A recent analyst article in Seeking Alpha assessed these three competitors and the state of play of their drug applications. The analysts considered these companies competitive threats to Amarin and its Vascepa drug.In addition, Amarin is facing patent lawsuits from several companies. These include Dr. Reddy's Laboratories (NYSE:RDY), an Indian pharmaceutical company, and Hikma Pharmaceuticals (OTCMKTS:HKMPY), a generic pharma company. However, bullish analysts point out that Teva (NYSE:TEVA) has already settled with Amarin.Most of these suits, including one that begins in January, concern the validity of the core of Amarin's patent family. It is called "Methods for treating hypertriglyceridemia." Another patent for "Stable pharmaceutical composition and methods of using same" family is also in litigation. * 5 Large-Cap Dividend Stocks to Buy If Amarin loses these cases, it could lose all patent protection. Other drug companies could use their ideas.As it stands the patents give Amarin protection until 2029, or 10 years. This is Amarin's only product, so it has to make hay during that period with Vascepa. What Should Investors Do?AMRN is a high-risk, high-return stock. As always, I recommend only buying on dips and during bad news with these kinds of stocks. They are essentially a mild form of gambling, although some risks can be minimalized with probability analysis.Given that a prior panel recommended for Vascepa, the AMRN stock price already discounted last week's FDA good news. Analysts seem to agree. Their target values are not significantly higher than the present price.Investors should look for an opportune time to jump in. Analysts will likely scrutinize the patent protection litigation closely in January. Look for an opportunity then to consider investing in Amarin stock.As of this writing, Mark Hake, CFA does not hold a position in any of the aforementioned securities. Mark Hake runs the Total Yield Value Guide which you can review here. The Guide focuses on high total yield value stocks. Subscribers a two-week free trial. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 8 Biggest Investing Surprises of 2019 * 7 Impressive Stocks to Buy Over $250 * 4 Small-Cap Energy Stocks Ready to Explode The post Amarin Stock is at Sky-High Levels Already Assumes All the Good News appeared first on InvestorPlace.

  • GlobeNewswire

    Matinas BioPharma Announces Feasibility Evaluation with Third Large Biopharmaceutical Company for the Formulation of Compounds Utilizing LNC Delivery Platform

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that it has entered into a feasibility evaluation with Genentech, a member of the Roche Group. This feasibility evaluation will involve the development of oral formulations using Matinas’ lipid nano-crystal (LNC) platform delivery technology, which enables the development of a wide range of difficult-to-deliver molecules. The interest shown by these companies in applying our platform delivery technology to their compounds is indicative of the emerging importance of drug delivery in the advancement of medicine.

  • GuruFocus.com

    Matinas Rides Amarin's Coattails as Vascepa Wins FDA Panel Vote

    Amarin's omega 3 fatty acid drug Vascepa is now closer to being blockbuster with an FDA panel vote win Continue reading...

  • GlobeNewswire

    Matinas BioPharma to Present at the 31st Annual Piper Jaffray Healthcare Conference

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a company overview, as well as host investor meetings, at the 31st Annual Piper Jaffray Healthcare Conference. Investors interested in arranging a meeting with the Company's management during this conference should contact the conference coordinator. A live audio webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (www.matinasbiopharma.com).

  • Barrons.com

    Amarin Stock Is Rising After Favorable Vote on Fish-Based Heart Drug

    An advisory panel voted to recommend that the Food and Drug Administration allow doctors to prescribe Vascepa to prevent heart attacks and strokes.

  • MarketWatch

    Amarin shares rise in premarket trading on FDA adcom vote for new label

    Shares of Amarin Corp. are up about 6% in premarket trading after a U.S. Food and Drug Administration advisory committee on Thursday voted 16-0 in favor of a broader label for the company's prescription fish oil-derived pill. The FDA is expected to decide on the new label by Dec. 28. If approved, Vascepa would be marketed as a treatment to lower the risk of cardiovascular events, like heart attacks or strokes. This label expansion would also likely expand the size of the patient population from 4 million to more than 40 million, according to Maxim Group analyst Jason McCarthy. "In our view, the market has the potential to be statin-like in size," he wrote in a note Friday. Stifel estimates $3 billion peak sales of Vascepa. Shares of Matinas BioPharma Holdings , which is developing a similar drug to Vascepa, also rose in premarket market trading, up 14%. Amarin stock has jumped 57.9% year-to-date, while the S&P 500 is up 23%.

  • Matinas Biopharma Holdings, Inc. (MTNB) Reports Q3 Loss, Misses Revenue Estimates
    Zacks

    Matinas Biopharma Holdings, Inc. (MTNB) Reports Q3 Loss, Misses Revenue Estimates

    Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Matinas BioPharma Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    – Initiated pre-screening of patients for Phase 2 ENHANCE-IT study of MAT9001 against Vascepa®. Enrollment to commence Q1 2020, with topline data expected H2 2020 – – NIH-funded.

  • GlobeNewswire

    Matinas BioPharma to Webcast Conference Call Discussing Third Quarter 2019 Operational and Financial Results on November 13, 2019

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live webcast on Wednesday, November 13, 2019 at 8:00 a.m. ET to discuss operational and financial results for the quarter ended September 30, 2019, as well as provide a corporate update. Matinas BioPharma is a clinical-stage biopharmaceutical company focused on development of its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions. MAT9001 is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, under development for hypertriglyceridemia, that was specifically designed to overcome the shortcomings seen from other agents in the omega-3 class.

  • Should You Be Concerned About Matinas BioPharma Holdings, Inc.'s (NYSEMKT:MTNB) Historical Volatility?
    Simply Wall St.

    Should You Be Concerned About Matinas BioPharma Holdings, Inc.'s (NYSEMKT:MTNB) Historical Volatility?

    If you're interested in Matinas BioPharma Holdings, Inc. (NYSEMKT:MTNB), then you might want to consider its beta (a...

  • GlobeNewswire

    Matinas BioPharma Initiates EnACT Study of MAT2203 (Oral Amphotericin B) for the Treatment of Fungal Cryptococcal Meningitis

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that it has initiated its Phase 2 EnACT clinical study, which will explore the use of MAT2203 for both induction and maintenance therapy in HIV-patients with cryptococcal meningitis, a life-threatening fungal infection most commonly observed in immunocompromised individuals. “We are extremely pleased to advance clinical development of MAT2203 for the treatment of cryptococcal meningitis,” commented Theresa Matkovits, Ph.D., Chief Development Officer of Matinas. “Antifungal resistance poses a major threat to the lives of vulnerable immunocompromised patients, and MAT2203 could provide an invaluable oral and safe treatment for severe fungal infections in these patients.

  • GlobeNewswire

    Matinas BioPharma Receives Orphan Drug Designation From U.S. FDA for MAT2203 for the Treatment of Cryptococcosis

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MAT2203, Matinas’ proprietary oral amphotericin B product, for the treatment of cryptococcosis, a life-threatening fungal infection most commonly observed in immunocompromised individuals. MAT2203 is Matinas’ orally-administered formulation of the broad-spectrum fungicidal medication amphotericin B, which is currently in Phase 2 clinical development.

  • GlobeNewswire

    Matinas BioPharma to Present at the 2019 Cantor Global Healthcare Conference

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that Jerome D. Jabbour, Chief Executive Officer, will present a company overview, as well as host investor meetings, at the 2019 Cantor Global Healthcare Conference. Investors interested in arranging a meeting with the Company's management during this conference should contact the conference coordinator. A live audio webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (www.matinasbiopharma.com).

  • GlobeNewswire

    Matinas BioPharma Announces Pre-Screening of Patients to Determine Eligibility for Phase 2 ENHANCE-IT Study Against Vascepa®

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that it has commenced pre-screening patients to determine eligibility for ENHANCE-IT, its Phase 2 head-to-head pharmacodynamic (PD) study of MAT9001 against Vascepa in patients with elevated triglycerides (150-499 mg/dL). “Our second head-to-head trial against Vascepa is an important milestone for our Company, and pre-screening patients for eligibility will facilitate rapid enrollment in the first quarter of 2020,” commented Jerome D. Jabbour, Chief Executive Officer of Matinas. The “ENHANCE-IT trial (Pharmacodynamic effects of a free fatty acid formulation of omega-3 pentaenoic acids to enhance efficacy in adults with elevated triglycerides) will be led by Kevin C. Maki, Ph.D., President and Chief Scientist of Midwest Biomedical Research, and is expected to involve approximately six sites in the United States.

  • Matinas BioPharma Holdings (NYSEMKT:MTNB) Is In A Good Position To Deliver On Growth Plans
    Simply Wall St.

    Matinas BioPharma Holdings (NYSEMKT:MTNB) Is In A Good Position To Deliver On Growth Plans

    Just because a business does not make any money, does not mean that the stock will go down. For example, although...

  • GlobeNewswire

    Matinas BioPharma to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that Jerome D. Jabbour, Chief Executive Officer, will present a company overview, as well as host investor meetings, at the H.C. Wainwright 21st Annual Global Investment Conference. Investors interested in arranging a meeting with the Company's management during this conference should contact the conference coordinator. A live audio webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (www.matinasbiopharma.com).

  • Thomson Reuters StreetEvents

    Edited Transcript of MTNB earnings conference call or presentation 13-Aug-19 12:00pm GMT

    Q2 2019 Matinas BioPharma Holdings Inc Earnings Call

  • Is Matinas BioPharma Holdings (NYSEMKT:MTNB) Using Debt Sensibly?
    Simply Wall St.

    Is Matinas BioPharma Holdings (NYSEMKT:MTNB) Using Debt Sensibly?

    The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...